News

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:...

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan...

If successful, REC-2282 could be the first approved treatment for NF2-mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per year REC-2282 has been...

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:

Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical trial for progressive...

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor...

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food and Drug Administration (FDA) has granted...

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:

The total capital represents the largest seed financing for life science startups in Utah's history SALT LAKE CITY, March 30, 2022 /PRNewswire/ -- Altitude Lab today announced its first cohort of...

Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments focused on...